PBRM1 and cancer: According to the subgroup analyses, PBRM1-MUT showed an apparent survival advantage over PBRM1-WT, regardless of age, sex, cancer type (except for BLCA), drug class, and TMB level (except for TMB high) (p > .05, Figure 2F).